Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $39.32 Consensus Price Target from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received an average recommendation of “Hold” from the thirty research firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and nine have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $39.32.

A number of equities research analysts have recently issued reports on SRPT shares. Weiss Ratings reissued a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Saturday, September 27th. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Morgan Stanley increased their price target on shares of Sarepta Therapeutics from $15.00 to $20.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 29th. TD Cowen downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $24.00 price target on the stock. in a report on Wednesday, June 18th. Finally, Leerink Partnrs downgraded shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, July 18th.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $22.64 on Friday. The company has a market cap of $2.21 billion, a PE ratio of -26.02 and a beta of 0.51. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $138.81. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The firm’s 50-day simple moving average is $18.39 and its two-hundred day simple moving average is $32.22.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating the consensus estimate of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company’s revenue was up 68.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.07 earnings per share. Research analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Byrne Asset Management LLC purchased a new stake in Sarepta Therapeutics in the first quarter valued at approximately $30,000. Center for Financial Planning Inc. purchased a new stake in Sarepta Therapeutics in the first quarter valued at approximately $31,000. Ancora Advisors LLC raised its stake in Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. Pandora Wealth Inc. purchased a new stake in Sarepta Therapeutics in the first quarter valued at approximately $45,000. Finally, Brooklyn Investment Group raised its stake in Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 590 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.